Peer Review History
| Original SubmissionMay 27, 2020 |
|---|
|
PONE-D-20-15837 The gestational low-protein intake impact in microRNA expression of the kidney progenitor cells in male offspring fetuses PLOS ONE Dear Dr. Gontijo, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process, especially those raised by reviewer 2. Please submit your revised manuscript by Aug 28 2020 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. Please include the following items when submitting your revised manuscript:
If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter. If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols We look forward to receiving your revised manuscript. Kind regards, Emmanuel A Burdmann Academic Editor PLOS ONE Journal Requirements: When submitting your revision, we need you to address these additional requirements. 1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and 2. Please include further information regarding your in vivo study, per our guidelines (http://journals.plos.org/plosone/s/submission-guidelines#loc-animal-research). Specifically, please provide details regarding: 1) Animal health monitoring, including: -frequency of monitoring, and -monitoring criteria 2) the method of euthanasia for the rats, and 3) the source of the mice 3. Please provide the missing information for Anti-mTOR in Table 1. 4. We note that Figures 9 and 10 appear to be similar to several general textbook mTOR diagrams. Because many pathway diagrams look similar even if they are not derived from each other, please verify that these figures are your own work and were not derived in part or full from copyrighted images. If they were derived from copyrighted images, you will need to get permissions from the copyright owner. If this is the case, please provide proof that the owner of the content (a) has given you written permission to use it, and (b) has approved of the CC BY license being applied to their content. You may have the following form completed by the owner as proof: https://journals.plos.org/plosone/s/file?id=7c09/content-permission-form.pdf. Alternatively, you may electronically request permissions electronically from the copyright owner and send us proof of approval, as long as the approval clearly shows that the owner has approved of the CC BY license being applied to their content. Please see https://journals.plos.org/plosone/s/licenses-and-copyright for more information. 5. We suggest you thoroughly copyedit your manuscript for language usage, spelling, and grammar. If you do not know anyone who can help you do this, you may wish to consider employing a professional scientific editing service. Whilst you may use any professional scientific editing service of your choice, PLOS has partnered with both American Journal Experts (AJE) and Editage to provide discounted services to PLOS authors. Both organizations have experience helping authors meet PLOS guidelines and can provide language editing, translation, manuscript formatting, and figure formatting to ensure your manuscript meets our submission guidelines. To take advantage of our partnership with AJE, visit the AJE website (http://learn.aje.com/plos/) for a 15% discount off AJE services. To take advantage of our partnership with Editage, visit the Editage website (www.editage.com) and enter referral code PLOSEDIT for a 15% discount off Editage services. If the PLOS editorial team finds any language issues in text that either AJE or Editage has edited, the service provider will re-edit the text for free. Upon resubmission, please provide the following:
6. Your ethics statement must appear in the Methods section of your manuscript. If your ethics statement is written in any section besides the Methods, please move it to the Methods section and delete it from any other section. Please also ensure that your ethics statement is included in your manuscript, as the ethics section of your online submission will not be published alongside your manuscript. [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions Comments to the Author 1. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. Reviewer #1: Yes Reviewer #2: Partly ********** 2. Has the statistical analysis been performed appropriately and rigorously? Reviewer #1: Yes Reviewer #2: Yes ********** 3. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified. Reviewer #1: Yes Reviewer #2: Yes ********** 4. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here. Reviewer #1: Yes Reviewer #2: No ********** 5. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters) Reviewer #1: LB Sene et al. developed an interesting study to evaluate mechanisms responsible for renal structural changes in 17-day-old fetuses of pregnant rats fed a low-protein diet or a diet with normal protein content. The study was very well planned and had as main objective to evaluate micro RNAs and gene and protein expression of several factors. The authors observed relevant differences between the experimental and control groups. These results allows to understand some of the mechanisms responsible for the smaller number of nephrons observed in the offspring of rats subjected to malnutrition during pregnancy. The manuscript needs a detailed correction of spelling and writing errors. As examples, I would like to draw your attention to some of the following necessary corrections. Page 10, line 9: replace graph with figure. Page 12, line four from bottom: replace which with with. Page 12, line three from bottom: replace could by may Page 13, line 4: replace "also, here, was demonstrated" by was observed. These are just a few of the many errors in the manuscript. In the legend of figure 1, explain the meaning of U6. The legends of tables 1 and 2 are switched. It would be interesting to mention some limitations of the study. Reviewer #2: The manuscript by Sene et al analyzes the impact of maternal protein restriction on molecular aspects of renal development in mice, and reveals that such a restriction modifies the miRNA, mRNA and protein expression scenarios associated with proliferation, apoptosis and differentiation. This is a relevant and timely field of investigation and, in general, the study was adequately performed. The manuscript carries language problems, however, since the English quality is not good, particularly in the discussion. Such problems include grammatical mistakes, sentences that do not allow appropriate understanding (examples shown below in comment #3) and flaws in sentence structure that make the reading sometimes difficult. In this context, the paper should be assessed and have some portions rewritten by a native English speaker. In addition, a number of points should be addressed, clarified or modified before further evaluation. Additional analyses should be also performed for adequate interpretation of some of the data and to allow appropriate conclusions. These points are outlined in my comments below. 1. The authors have carried out the miRNA expression analyses based on statistically significant differences between the LP and NP groups, but have not established a fold-change cutoff for such analyses. They included, however, blue and red dashed lines to establish fold-change upregulation and downregulation thresholds in Figure 1. Some studies use a 2-fold-change cutoff, other studies 1.5 (less often), but such criteria are arbitrary. It is important, however, that the authors define whether they used or not a fold-change cutoff. If they did, please be clear about it and justify the decision. If they did not, please justify why they decided not to use any filtering criteria and explain what and how they defined the fold-change values associated with the blue and red up and down dashed lines. 2. Please also address the fold-change issue to the mRNA context in Figure 2. 3. Examples of inappropriate/unclear sentences: ... predicted gene expression patterns in the 17-days LP (17-DG) fetal kidney to elucidate the molecular pathways and differentiation renal cell proliferation. Prior studies have shown that during kidney development, the miRNAs underexpression MM progenitor cells results in a premature reduction of cell proliferation and ... In the current study, increased expression of miR-181a-5p in 17-DG LP relative to age-matched NP offspring; also, here, was demonstrated a 2-fold enhanced Bax/Bcl2 mRNA ratio … … they also showed that enhanced miR-144 expression suppresses renal carcinoma proliferation and decreasing the G2/M phase cells ratio. The let-7 miRNA family expression has been extensively studied in several fetal tissues and, priority is related with reduced proliferation and induced cell differentiation. It has been shown in higher organisms, enhanced let-7 levels during embryogenesis (Schulman et al., 2005), and let-7a mature form is up-regulated during the developmental mouse brain. How is it known that Six2 regulates transcription of GDNF (Brodbeck et al., 2004), thus, the reduction of 28% in the cells positive for Six2 could affect, in the same proportion the GDNF expression which in turn, would act in … 4. The study associates increased expression of miR 181a-5p in 17-DG LP offspring with increased Bax/Bcl2 mRNA ratio to explain increased apoptosis activity, despite no change in caspase mRNA expression. Since Bax overexpression has been shown to induce caspase-independent apoptosis and cordycepol C has been shown to induce caspase-independent apoptosis in HepG2 cells through a Bax-mediated mitochondrial pathway, I suggest to investigate caspase-independent mechanisms of apoptosis in 17-DG LP fetal kidneys. 5. Please discuss potential mechanisms relating reduced expression of miR-144-3p in 17-DG LP offspring CAP and decreased cell proliferation. 6. As pointed out by the authors, increased activity of mTOR led to nephron number reduction in fetal kidneys while hemizygous removal of mTOR also diminishes nephron population. Is there a narrow range of mTOR activity during nephrogenesis that appropriately regulates nephron number? Please discuss this issue and apply this discussion to analyze the current model. 7. Please clarify the sentence “Increased mRNA accompanied the reduction of miR 127-3p in 17-DG LP offspring for Ki67 associated with an increase of Bcl-6 in CM”. 8. Because Ki67 gene expression is increased and Ki-67 immunoreactivity is decreased in LP 17-DG metanephros, the authors state that gestational undernutrition promotes differentiation in detriment of proliferation. If so, this is a post-transcriptional mechanism. Please discuss how that may occur, cite other models in which a similar process occurred, and clarify the association with Zeb2 expression. 9. Please clarify the sentence “On the other hand, Yermalovich et al. (2019) have demonstrated the overexpression of Lin28b, an RNA-binding protein, is associated with suppressive let-7 miRNA expression elongated nephrogenesis, via the let-7 miRNAs upregulation.” 10. Since the authors hypothesize that overexpression of let-7 miRNAs, through a transient reduction of LIN28B, might decrease nephrogenesis and consequently the nephron number potentially via upregulation of Igf2, I recommend them to check Igf2 expression in the current LP model. 11. The authors state that “the current study established that the let-7 family of miRNAs promotes MYC expression through transcriptionally induced let-7 repressor, LIN28 enhancement and posttranscriptional expressed LIN28 RNA binding-protein, promoting downregulation upon LP kidney cells differentiation”, however there is no generated data on let-7 repressor and/or Lin28 that support this conclusion. 12. Notch signaling has been shown to promote nephrogenesis by downregulating Six2. In the current study, the authors show decreased Notch1 expression but unchanged Six2 expression and reduction of Six-2 positive cells in LP offspring metanephros. In this scenario, the statement “the increased let-7a-5p and β-catenin expression and reduced Notch signal modulate the c-myc, six2, and KI-67, leading to reduction of progenitor cells self-renewal in LP metanephros” should not be presented as a conclusion but instead as “suggests that the increased let-7a-5p and β-catenin expression and reduced Notch signal may modulate the c-myc, six2, and KI-67, leading to …”. 13. Given that c-Ret receptor tyrosine kinase is a major inducer of UB branching, the increase in c-Ret expression is expected to increase UB branching even if the expression of GDNF is unchanged. Moreover, despite the reduction of Six-2 positive cells, GDNF expression did not change. In this scenario, the current discussion does not seem to appropriately support the observed 28.3% reduction in UB branching. ********** 6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy. Reviewer #1: No Reviewer #2: No [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step. |
| Revision 1 |
|
PONE-D-20-15837R1 Impact of gestational low-protein intake on embryonic kidney microRNA expression and in the nephron progenitor cells of the male offspring fetus PLOS ONE Dear Dr. Gontijo, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process by reviewer 2. Please submit your revised manuscript by Jan 07 2021 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. Please include the following items when submitting your revised manuscript:
If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter. If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols We look forward to receiving your revised manuscript. Kind regards, Emmanuel A Burdmann Academic Editor PLOS ONE [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions Comments to the Author 1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation. Reviewer #2: (No Response) ********** 2. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. Reviewer #2: Yes ********** 3. Has the statistical analysis been performed appropriately and rigorously? Reviewer #2: Yes ********** 4. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified. Reviewer #2: Yes ********** 5. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here. Reviewer #2: Yes ********** 6. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters) Reviewer #2: The authors have significantly improved the manuscript, both scientifically and language-wise, however a number of flaws remain to be addressed. Specific comments follow below: 1. The authors were not as careful as they should be in their reply, copying and pasting their first response to reviewer 1 also as their first response to reviewer 2, including the term ”reviewer 1”. 2. It is unclear which experiments were redone; please specify them. 3. It is unclear which experiments had their numbers increased; please specify them. 4. It is true that the language quality improved, however the amount of sentence structure/clarity problems and grammatical mistakes remains above an acceptable level, both in the manuscript and in the reply to the reviewers. Please have the manuscript go through a native English speaker. 5. The authors have appropriately addressed my previous major comments 1 and 2, however such a point is unclear in the current manuscript. Please add this information to the revised version of the manuscript. 6. The modified versions of sentences 3.1 and 3.7 (re: previous major comment 3) are understandable but remain inappropriately written. 7. As a follow-up to my previous major comment 4, the authors state that they are currently performing studies to investigate autophagy and apoptosis pathways in nephron progenitor cells of metanephric mesenchyme during renal development, in the offspring of mice submitted to gestational protein restriction. Please include such data, at least part of them, in the current manuscript. 8. The authors have addressed my previous major comments 7, 11 and 12, however there are significant English problems in the corresponding texts. 9. My previous major comment 10 was not properly addressed, since the authors’ statement “the current study established that the let-7 family of miRNAs promotes MYC expression through transcriptionally induced let-7 repressor, LIN28 enhancement and posttranscriptional expressed LIN28 RNA binding-protein, promoting downregulation upon LP kidney cells differentiation” would require generation of data on Lin28 expression. ********** 7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy. Reviewer #2: No [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step. |
| Revision 2 |
|
PONE-D-20-15837R2 Impact of gestational low-protein intake on embryonic kidney microRNA expression and in the nephron progenitor cells of the male offspring fetus PLOS ONE Dear Dr. Gontijo, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the minor points raised during the review process. Please submit your revised manuscript by Feb 04 2021 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. Please include the following items when submitting your revised manuscript:
If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter. If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols We look forward to receiving your revised manuscript. Kind regards, Emmanuel A Burdmann Academic Editor PLOS ONE [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions Comments to the Author 1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation. Reviewer #2: (No Response) ********** 2. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. Reviewer #2: Yes ********** 3. Has the statistical analysis been performed appropriately and rigorously? Reviewer #2: Yes ********** 4. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified. Reviewer #2: Yes ********** 5. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here. Reviewer #2: Yes ********** 6. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters) Reviewer #2: My comments have been adequately addressed or justified, however two points remain to be fulfilled/considered. 1. The language quality gave one more step ahead, however it still needs improvement to reach an appropriate level. Incomplete sentences, inappropriately structured sentences and grammatical errors are still frequent, particularly in the discussion. At this point, therefore, my recommendation is to have an editing service review the manuscript. 2. The authors are presently performing studies to investigate autophagy and apoptosis pathways in nephron progenitor cells of metanephric mesenchyme during renal development in the offspring of mice submitted to gestational protein restriction. Initial data have been generated. Given the relevance of this issue to the present study and the additional time from the last revision, do the current results include any significantly robust piece of data that could expand this aspect in the present manuscript? ********** 7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy. Reviewer #2: No [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step. |
| Revision 3 |
|
Impact of gestational low-protein intake on embryonic kidney microRNA expression and in nephron progenitor cells of the male fetus PONE-D-20-15837R3 Dear Dr. Gontijo, We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements. Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication. An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org. If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org. Kind regards, Emmanuel A Burdmann Section Editor PLOS ONE Additional Editor Comments (optional): Reviewers' comments: Reviewer's Responses to Questions Comments to the Author 1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation. Reviewer #2: All comments have been addressed ********** 2. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. Reviewer #2: (No Response) ********** 3. Has the statistical analysis been performed appropriately and rigorously? Reviewer #2: (No Response) ********** 4. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified. Reviewer #2: (No Response) ********** 5. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here. Reviewer #2: (No Response) ********** 6. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters) Reviewer #2: (No Response) ********** 7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy. Reviewer #2: No |
| Formally Accepted |
|
PONE-D-20-15837R3 Impact of gestational low-protein intake on embryonic kidney microRNA expression and in nephron progenitor cells of the male fetus Dear Dr. Gontijo: I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department. If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org. If we can help with anything else, please email us at plosone@plos.org. Thank you for submitting your work to PLOS ONE and supporting open access. Kind regards, PLOS ONE Editorial Office Staff on behalf of Dr. Emmanuel A Burdmann Section Editor PLOS ONE |
Open letter on the publication of peer review reports
PLOS recognizes the benefits of transparency in the peer review process. Therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. Reviewers remain anonymous, unless they choose to reveal their names.
We encourage other journals to join us in this initiative. We hope that our action inspires the community, including researchers, research funders, and research institutions, to recognize the benefits of published peer review reports for all parts of the research system.
Learn more at ASAPbio .